Management of immunotherapy-related toxicities, version 1.2019

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Brianna Hoffner, Christopher J. Hoimes, Mario Lacouture, Frederick Locke, Matthew A Lunning, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski & 11 others Olalekan Oluwole, Sandip P. Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.

Original languageEnglish (US)
Pages (from-to)255-289
Number of pages35
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Immunotherapy
Guidelines
Oncology Nursing
Patient Advocacy
Neoplasms
Antigen Receptors
Nephrology
Emergency Medicine
Gastroenterology
Cell- and Tissue-Based Therapy
Dermatology
Cardiology

ASJC Scopus subject areas

  • Oncology

Cite this

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., ... Scavone, J. L. (2019). Management of immunotherapy-related toxicities, version 1.2019. JNCCN Journal of the National Comprehensive Cancer Network, 17(3), 255-289. https://doi.org/10.6004/jnccn.2019.0013

Management of immunotherapy-related toxicities, version 1.2019. / Thompson, John A.; Schneider, Bryan J.; Brahmer, Julie; Andrews, Stephanie; Armand, Philippe; Bhatia, Shailender; Budde, Lihua E.; Costa, Luciano; Davies, Marianne; Dunnington, David; Ernstoff, Marc S.; Frigault, Matthew; Hoffner, Brianna; Hoimes, Christopher J.; Lacouture, Mario; Locke, Frederick; Lunning, Matthew A; Mohindra, Nisha A.; Naidoo, Jarushka; Olszanski, Anthony J.; Oluwole, Olalekan; Patel, Sandip P.; Reddy, Sunil; Ryder, Mabel; Santomasso, Bianca; Shofer, Scott; Sosman, Jeffrey A.; Wahidi, Momen; Wang, Yinghong; Johnson-Chilla, Alyse; Scavone, Jillian L.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 17, No. 3, 01.03.2019, p. 255-289.

Research output: Contribution to journalArticle

Thompson, JA, Schneider, BJ, Brahmer, J, Andrews, S, Armand, P, Bhatia, S, Budde, LE, Costa, L, Davies, M, Dunnington, D, Ernstoff, MS, Frigault, M, Hoffner, B, Hoimes, CJ, Lacouture, M, Locke, F, Lunning, MA, Mohindra, NA, Naidoo, J, Olszanski, AJ, Oluwole, O, Patel, SP, Reddy, S, Ryder, M, Santomasso, B, Shofer, S, Sosman, JA, Wahidi, M, Wang, Y, Johnson-Chilla, A & Scavone, JL 2019, 'Management of immunotherapy-related toxicities, version 1.2019', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 3, pp. 255-289. https://doi.org/10.6004/jnccn.2019.0013
Thompson, John A. ; Schneider, Bryan J. ; Brahmer, Julie ; Andrews, Stephanie ; Armand, Philippe ; Bhatia, Shailender ; Budde, Lihua E. ; Costa, Luciano ; Davies, Marianne ; Dunnington, David ; Ernstoff, Marc S. ; Frigault, Matthew ; Hoffner, Brianna ; Hoimes, Christopher J. ; Lacouture, Mario ; Locke, Frederick ; Lunning, Matthew A ; Mohindra, Nisha A. ; Naidoo, Jarushka ; Olszanski, Anthony J. ; Oluwole, Olalekan ; Patel, Sandip P. ; Reddy, Sunil ; Ryder, Mabel ; Santomasso, Bianca ; Shofer, Scott ; Sosman, Jeffrey A. ; Wahidi, Momen ; Wang, Yinghong ; Johnson-Chilla, Alyse ; Scavone, Jillian L. / Management of immunotherapy-related toxicities, version 1.2019. In: JNCCN Journal of the National Comprehensive Cancer Network. 2019 ; Vol. 17, No. 3. pp. 255-289.
@article{85c195f025694857a4bd57c247e4829c,
title = "Management of immunotherapy-related toxicities, version 1.2019",
abstract = "The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.",
author = "Thompson, {John A.} and Schneider, {Bryan J.} and Julie Brahmer and Stephanie Andrews and Philippe Armand and Shailender Bhatia and Budde, {Lihua E.} and Luciano Costa and Marianne Davies and David Dunnington and Ernstoff, {Marc S.} and Matthew Frigault and Brianna Hoffner and Hoimes, {Christopher J.} and Mario Lacouture and Frederick Locke and Lunning, {Matthew A} and Mohindra, {Nisha A.} and Jarushka Naidoo and Olszanski, {Anthony J.} and Olalekan Oluwole and Patel, {Sandip P.} and Sunil Reddy and Mabel Ryder and Bianca Santomasso and Scott Shofer and Sosman, {Jeffrey A.} and Momen Wahidi and Yinghong Wang and Alyse Johnson-Chilla and Scavone, {Jillian L.}",
year = "2019",
month = "3",
day = "1",
doi = "10.6004/jnccn.2019.0013",
language = "English (US)",
volume = "17",
pages = "255--289",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",

}

TY - JOUR

T1 - Management of immunotherapy-related toxicities, version 1.2019

AU - Thompson, John A.

AU - Schneider, Bryan J.

AU - Brahmer, Julie

AU - Andrews, Stephanie

AU - Armand, Philippe

AU - Bhatia, Shailender

AU - Budde, Lihua E.

AU - Costa, Luciano

AU - Davies, Marianne

AU - Dunnington, David

AU - Ernstoff, Marc S.

AU - Frigault, Matthew

AU - Hoffner, Brianna

AU - Hoimes, Christopher J.

AU - Lacouture, Mario

AU - Locke, Frederick

AU - Lunning, Matthew A

AU - Mohindra, Nisha A.

AU - Naidoo, Jarushka

AU - Olszanski, Anthony J.

AU - Oluwole, Olalekan

AU - Patel, Sandip P.

AU - Reddy, Sunil

AU - Ryder, Mabel

AU - Santomasso, Bianca

AU - Shofer, Scott

AU - Sosman, Jeffrey A.

AU - Wahidi, Momen

AU - Wang, Yinghong

AU - Johnson-Chilla, Alyse

AU - Scavone, Jillian L.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.

AB - The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.

UR - http://www.scopus.com/inward/record.url?scp=85062877270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062877270&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0013

DO - 10.6004/jnccn.2019.0013

M3 - Article

VL - 17

SP - 255

EP - 289

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 3

ER -